GAA
BEAM icon

Green Alpha Advisors’s Beam Therapeutics BEAM Stock Holding History

Green Alpha Advisors’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-7,569
Closed -$260K – 111
2026
Q2 		$260K Buy
+7,569
New +$229K 0.17% 90
2026
Q1 		– Sell
-8,517
Closed -$236K – 109
2025
Q4 		$236K Buy
+8,517
New +$217K 0.22% 98
2025
Q1 		– Sell
-10,192
Closed -$253K – 116
2024
Q4 		$253K Sell
10,192
-2,283
-18% -$58.3K 0.2% 119
2024
Q3 		$306K Buy
12,475
+698
+6% +$18K 0.24% 110
2024
Q2 		$276K Sell
11,777
-1,859
-14% -$45.7K 0.22% 108
2024
Q1 		$451K Sell
13,636
-273
-2% -$8.51K 0.33% 104
2023
Q4 		$379K Sell
13,909
-1,665
-11% -$41.4K 0.27% 120
2023
Q3 		$375K Buy
15,574
+3,083
+25% +$82.6K 0.29% 114
2023
Q2 		$399K Buy
12,491
+2,229
+22% +$72.3K 0.26% 119
2023
Q1 		$314K Sell
10,262
-28
-0.3% -$1.1K 0.22% 126
2022
Q4 		$402K Buy
10,290
+467
+5% +$20.9K 0.33% 107
2022
Q3 		$468K Buy
9,823
+54
+0.6% +$3.08K 0.4% 112
2022
Q2 		$378K Buy
+9,769
New +$388K 0.09% 135

Other funds holding BEAM

FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

Green Alpha Advisors's BEAM Position: Q3 2026 in Review

Green Alpha Advisors sold out of Beam Therapeutics (BEAM) in Q3 2026, closing a stake of 7,569 shares — an estimated $260K sold.

Green Alpha Advisors first reported a position in BEAM in Q2 2022 and held it in 13 quarters. The position peaked at $468K in Q3 2022. 4 funds tracked by Wall St. Rank hold BEAM as of Q3 2026.

  • Green Alpha Advisors reported no remaining Beam Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Green Alpha Advisors sold 7,569 Beam Therapeutics shares in Q3 2026, an estimated $260K.
  • Green Alpha Advisors first reported a position in Beam Therapeutics in Q2 2022 and held it in 13 quarters.
  • Green Alpha Advisors's Beam Therapeutics position peaked at $468K in Q3 2022.
  • 4 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2026.

Based on Green Alpha Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.